Autism spectrum disorders are an emerging health problem worldwide, but little is known about their pathogenesis.
It has been hypothesized that autism may result from an imbalance between excitatory glutamatergic and inhibitory GABAergic pathways.
Commonly used medications such as valproate, acamprosate, and arbaclofen may act on the GABAergic system and be a potential treatment for people with ASD.
The present systematic review aimed at evaluating the state-of-the-art of clinical trials of GABA modulators in autism.
To date there is insufficient evidence to suggest the use of these drugs in autistic subjects, even if data are promising.
Of note, short-term use of all the reviewed medications appears to be safe.
Future well designed trials are needed to elucidate these preliminary findings.
Oversett med Google Translate
-
